These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 19655143)

  • 21. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.
    Cohen AR; Galanello R; Piga A; De Sanctis V; Tricta F
    Blood; 2003 Sep; 102(5):1583-7. PubMed ID: 12763939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
    Cermak J; Jonasova A; Vondrakova J; Cervinek L; Belohlavkova P; Neuwirtova R
    Leuk Res; 2013 Dec; 37(12):1612-5. PubMed ID: 23937987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload.
    Payne KA; Rofail D; Baladi JF; Viala M; Abetz L; Desrosiers MP; Lordan N; Ishak K; Proskorovsky I
    Adv Ther; 2008 Aug; 25(8):725-42. PubMed ID: 18704280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.
    Calvaruso G; Vitrano A; Di Maggio R; Lai E; Colletta G; Quota A; Gerardi C; Rigoli LC; Sacco M; Pitrolo L; Maggio A
    Am J Hematol; 2015 Jul; 90(7):634-8. PubMed ID: 25809173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Future of oral iron chelator deferiprone. (L1) ICOC committee.
    Kontoghiorghes GJ; Agarwal MB; Tondury P; Kersten MJ; Jaeger M; Vreugdenhil G; Vania A; Rahman YE
    Lancet; 1993 Jun; 341(8858):1479-80. PubMed ID: 8099176
    [No Abstract]   [Full Text] [Related]  

  • 26. Safety profile of the oral iron chelator deferiprone: a multicentre study.
    Cohen AR; Galanello R; Piga A; Dipalma A; Vullo C; Tricta F
    Br J Haematol; 2000 Feb; 108(2):305-12. PubMed ID: 10691860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
    Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
    Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multi-center safety trial of the oral iron chelator deferiprone.
    Cohen A; Galanello R; Piga A; Vullo C; Tricta F
    Ann N Y Acad Sci; 1998 Jun; 850():223-6. PubMed ID: 9668543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia.
    Gomber S; Jain P; Sharma S; Narang M
    Indian Pediatr; 2016 Mar; 53(3):207-10. PubMed ID: 27029681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and adverse effects of oral iron chelator deferiprone (l1, 1,2- dimethyl-3-hydroxypyrid-4-one) in patients with beta thalassaemia major in Pakistan.
    Ayyub M; Ali W; Anwar M; Waqar A; Khan MN; Ijaz A; Hussain T; Hussain S
    J Ayub Med Coll Abbottabad; 2005; 17(4):12-5. PubMed ID: 16599026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Iron chelation therapy.
    Hoffbrand AV; Wonke B
    J Intern Med Suppl; 1997; 740():37-41. PubMed ID: 9350180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral deferiprone for iron chelation in people with thalassaemia.
    Roberts DJ; Brunskill SJ; Doree C; Williams S; Howard J; Hyde CJ
    Cochrane Database Syst Rev; 2007 Jul; (3):CD004839. PubMed ID: 17636775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload.
    ElAlfy MS; Sari TT; Lee CL; Tricta F; El-Beshlawy A
    J Pediatr Hematol Oncol; 2010 Nov; 32(8):601-5. PubMed ID: 20921906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long term deferiprone chelation therapy.
    Hoffbrand VA; Wonke B
    Adv Exp Med Biol; 2002; 509():127-39. PubMed ID: 12572992
    [No Abstract]   [Full Text] [Related]  

  • 36. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA; Foster RH
    Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
    Maggio A; Kattamis A; Felisi M; Reggiardo G; El-Beshlawy A; Bejaoui M; Sherief L; Christou S; Cosmi C; Della Pasqua O; Del Vecchio GC; Filosa A; Cuccia L; Hassab H; Kreka M; Origa R; Putti MC; Spino M; Telfer P; Tempesta B; Vitrano A; Tsang YC; Zaka A; Tricta F; Bonifazi D; Ceci A
    Lancet Haematol; 2020 Jun; 7(6):e469-e478. PubMed ID: 32470438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacotherapy of iron overload in thalassaemic patients.
    Ceci A; Felisi M; De Sanctis V; De Mattia D
    Expert Opin Pharmacother; 2003 Oct; 4(10):1763-74. PubMed ID: 14521486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined therapy with deferoxamine and deferiprone.
    Kattamis A
    Ann N Y Acad Sci; 2005; 1054():175-82. PubMed ID: 16339663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major.
    Waheed N; Ali S; Butt MA
    J Ayub Med Coll Abbottabad; 2014; 26(3):297-300. PubMed ID: 25671931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.